Literature DB >> 26001634

Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience.

Benjamin Terrier1, Agnès Dechartres2, Charlotte Girard3, Stéphane Jouneau4, Jean-Emmanuel Kahn5, Robin Dhote6, Estibaliz Lazaro7, Jean Cabane8, Thomas Papo9, Nicolas Schleinitz10, Pascal Cohen11, Edouard Begon12, Pauline Belenotti13, Dominique Chauveau14, Elisabeth Diot15, Thierry Généreau16, Mohamed Hamidou17, Gilles Hayem18, Guillaume Le Guenno19, Véronique Le Guern11, Marc Michel20, Guillaume Moulis21, Xavier Puéchal11, Sophie Rivière22, Maxime Samson23, François Gonin24, Claire Le Jeunne11, Pascal Corlieu25, Luc Mouthon11, Loic Guillevin.   

Abstract

OBJECTIVES: Tracheobronchial stenosis (TBS) is noted in 12-23% of patients with granulomatosis with polyangiitis (GPA), and includes subglottic stenosis and bronchial stenosis. We aimed to analyse the endoscopic management of TBS in GPA and to identify factors associated with the efficacy of endoscopic interventions.
METHODS: We conducted a French nationwide retrospective study that included 47 patients with GPA-related TBS.
RESULTS: Compared with patients without TBS, those with TBS were younger, more frequently female and had less frequent kidney, ocular and gastrointestinal involvement and mononeuritis multiplex. Endoscopic procedures included 137 tracheal and 50 bronchial interventions, mainly endoscopic dilatation, local steroid injection and conservative laser surgery, and less frequently stenting. After the first endoscopic procedure, the cumulative incidence of endoscopic treatment failure was 49% at 1 year, 70% at 2 years and 80% at 5 years. Factors significantly associated with a higher cumulative incidence of treatment failure were a shorter time from GPA diagnosis to endoscopic procedure [hazard ratio (HR) 1.08 (95% CI 1.01, 1.14); P = 0.01] and a bronchial stenosis [HR 1.96 (95% CI 1.28, 3.00); P = 0.002]. A prednisone dose ≥30 mg/day at the time of the procedure was associated with a lower cumulative incidence of treatment failure [HR 0.53 (95% CI 0.31, 0.89); P = 0.02].
CONCLUSION: TBS represents severe and refractory manifestations with a high rate of restenosis. High-dose systemic CSs at the time of the procedure and increased time from GPA diagnosis to bronchoscopic intervention are associated with a better event-free survival. In contrast, bronchial stenoses are associated with a higher rate of restenosis than subglottic stenosis.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  bronchial stenosis; dilatation; granulomatosis with polyangiitis; prosthesis; subglottic stenosis; tracheobronchial involvement

Mesh:

Substances:

Year:  2015        PMID: 26001634     DOI: 10.1093/rheumatology/kev129

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

1.  Granulomatosis with polyangiitis causing subglottic stenosis-two cases and their management.

Authors:  Victoria Blackabey; Richard Wei Chern Gan; Helen Buglass; Veena Kaul; Victoria M M Ward
Journal:  AME Case Rep       Date:  2018-04-30

2.  Factors Affecting Dilation Interval in Patients With Granulomatosis With Polyangiitis-Associated Subglottic and Glottic Stenosis.

Authors:  Lena W Chen; Ioan Lina; Kevin Motz; Alexandra J Berges; Rafael Ospino; Philip Seo; Alexander T Hillel
Journal:  Otolaryngol Head Neck Surg       Date:  2021-04-13       Impact factor: 3.497

3.  Ear, nose, throat and airways disease in granulomatosis with polyangiitis.

Authors:  Matthew L Coates; Lisa C Willcocks; Pasupathy Sivasothy; Marcos Martinez Del Pero
Journal:  Rheumatology (Oxford)       Date:  2021-06-17       Impact factor: 7.046

4.  Infectious complication or exacerbation of granulomatosis with polyangiitis?

Authors:  Anna Masiak; Małgorzata Struk-Panfill; Zbigniew Zdrojewski
Journal:  Reumatologia       Date:  2015-12-08

5.  A retrograde y-stenting of the trachea for treatment of mediastinal fistula in an unusual situation.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Michael Steinheimer; Thomas Schneider; Naim Benhassen; Holger Rupprecht; Lutz Freitag
Journal:  Ther Clin Risk Manag       Date:  2017-05-23       Impact factor: 2.423

6.  Doxycycline-Eluting Core-Shell Type Nanofiber-Covered Trachea Stent for Inhibition of Cellular Metalloproteinase and Its Related Fibrotic Stenosis.

Authors:  Rengarajan Baskaran; Un-Jeong Ko; Enkhzaya Davaa; Ji Eun Park; Yixin Jiang; Junghan Lee; Su-Geun Yang
Journal:  Pharmaceutics       Date:  2019-08-19       Impact factor: 6.321

7.  Severe tracheobronchial stenosis in granulomatosis with polyangiitis and type 2 respiratory failure.

Authors:  Gayatri Ekbote; Rajiva Gupta; Natasha Negalur; Dhaval Tanna
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.472

8.  Central airway obstruction: is it time to move forward?

Authors:  Fernando Guedes; Mariana V Branquinho; Ana C Sousa; Rui D Alvites; António Bugalho; Ana Colette Maurício
Journal:  BMC Pulm Med       Date:  2022-02-19       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.